MedDataX Logo

An Investigational Drug Study in Healthy Adult Volunteers in a Model of Insomnia (0928-007)

NCT ID: NCT00102154

Last Updated: 2015-01-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2005-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study to evaluate the safety and effectiveness of an investigational drug for insomnia (a sleep disorder).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia (0928-006)(COMPLETED)

NCT00102167

Insomnia
COMPLETED PHASE3

Adult Primary Insomnia Polysomnographic Study (0928-004)(COMPLETED)

NCT00094627

Primary Insomnia
COMPLETED PHASE3

Efficacy and Safety of MK0928 for Insomnia in Adults (0928-003)(COMPLETED)

NCT00095069

Insomnia
COMPLETED PHASE3

An Investigational Study of MK0928 in Adult Outpatients With Insomnia (0928-014)(COMPLETED)

NCT00103818

Insomnia
COMPLETED PHASE3

Safety of MK0928 on Insomnia in the Elderly (0928-005)(COMPLETED)

NCT00095043

Insomnia
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Insomnia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK0928, gaboxadol / Duration of Treatment: 10 months

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adults who are between the ages of 18 and 64

Exclusion Criteria

* Adults who are diagnosed with insomnia
Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

H. Lundbeck A/S

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Merck Sharp & Dohme Corp

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

Merck Sharp & Dohme LLC

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2004_093

Identifier Type: -

Identifier Source: secondary_id

0928-007

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)
NCT00266344 COMPLETED PHASE2
Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)
NCT00266357 TERMINATED PHASE2
Elderly Primary Insomnia Polysomnographic Study (0928-002)(TERMINATED)
NCT00094666 TERMINATED PHASE3
A Study of Gaboxadol in Primary Insomnia
NCT00209924 COMPLETED PHASE3
A Study of Gaboxadol in Primary Insomnia
NCT00209846 COMPLETED PHASE3
Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED)
NCT00420810 TERMINATED PHASE3
A Prospective Active-Reference Study of Gaboxadol in Primary Insomnia
NCT00209937 COMPLETED PHASE3
A Study of Gaboxadol in Primary Insomnia
NCT00209963 COMPLETED PHASE3
Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)
NCT01021852 COMPLETED PHASE2
A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia
NCT00209950 COMPLETED PHASE3
Effects Of GW679769 On Sleep Onset And Maintenance And Next Day Functioning In Subjects With Primary Insomnia
NCT00280423 COMPLETED PHASE2
An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient Insomnia
NCT03338764 WITHDRAWN PHASE3
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274
NCT02852395 COMPLETED PHASE1
To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia
NCT00426816 COMPLETED PHASE2
Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity
NCT02464046 COMPLETED PHASE2
A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)
NCT01021813 COMPLETED PHASE3
Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)
NCT00792298 COMPLETED PHASE2
Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary Insomnia
NCT00280436 COMPLETED PHASE2
Suvorexant and Trauma Related Insomnia
NCT02704754 COMPLETED PHASE4
Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder
NCT02841709 COMPLETED PHASE2
A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia
NCT00551148 COMPLETED PHASE2
Appraising Clinical Trial Experiences of Patients With Insomnia
NCT05978271 NOT_YET_RECRUITING
Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary Insomnia
NCT00354809 COMPLETED PHASE2
A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP441 in Sleep-deprived Healthy Participants
NCT05651152 COMPLETED PHASE1
A Study of the Safety of Gabapentin in a Potential Over-the-Counter Population With Occasional Sleeplessness
NCT00666575 COMPLETED PHASE3